Since the establishment in 2007 as a new drug development company specializing in clinical
development of novel drugs, Kainos Medicine has successfully carried out Phase I clinical study for
HIV/AIDS medication in Korea and Phase II clinical study for xerostama (mouth dryness)
in the United States.
Starting with the development of diabetic/obesity medication in 2010,
we have proceeded with drug development for epigenetic anti-cancer agents in 2012 and
have switched to a parallel system to carry out both clinical development and
discovery research for novel compounds.

As a result of those efforts, Kainos Medicine has successfully transferred
technology of medications for HIV/AIDS medication, diabetic/obesity,
and two anti-cancer agents to the Chinese company.
As part of our strategy for entry into the Chinese market, we established a partnership with a Chinese
pharmaceutical company to carry out preclinical and early clinical studies on the HIV/AIDS
and two anti-cancer agents.

In 2015, Kainos Medicine expanded its R&D scope to develop novel drug for the treatment of Parkinson's disease.
Despite of high needs, there are no appropriate and effective medications for Parkinson's disease.
We will continue to concentrate our competencies on selective clinical development of medicine that will be influential to the market.

Additionally, Kainos Medicine hopes to bring an expeditious success through our network of researchers with global experience in drug development, maximizing our company's core competency in medicinal chemistry technology, and utilizing researchers in the development of immuno-oncologic agents, a new area of anti-cancer research.

We, as a venture company, are enhancing our global competitiveness in research and development through various joint partnership.

To accomplish successful drug development through the maximization of our core competencies, Kainos Medicine is proactively partnering with universities, research institutes, pharmaceutical companies, and biotechnology companies in Korea and overseas that have complementary technologies for joint research and technology transfers. Our revenue model is to create profit through technology transfers by enhancing our global competitiveness in research and development.